Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity.

Bello NT.

Expert Opin Drug Saf. 2019 Jul;18(7):549-552. doi: 10.1080/14740338.2019.1618268. Epub 2019 May 17. No abstract available.

PMID:
31092063
2.

Perioperative Pain Management of a Patient Taking Naltrexone HCl/Bupropion HCl (Contrave): A Case Report.

Ninh A, Kim S, Goldberg A.

A A Case Rep. 2017 Oct 15;9(8):224-226. doi: 10.1213/XAA.0000000000000573.

PMID:
28604472
3.

Obesity Epidemic: Pharmaceutical Weight Loss.

Curry SA.

R I Med J (2013). 2017 Mar 1;100(2):18-20.

PMID:
28246654
4.

Acute Generalized Erythrodermic Pustular Psoriasis Associated with Bupropion/Naltrexone (Contrave®).

Singh PA, Cassel KP, Moscati RM, Eckersley D.

J Emerg Med. 2017 Apr;52(4):e111-e113. doi: 10.1016/j.jemermed.2016.11.034. Epub 2017 Jan 24.

PMID:
28130024
5.
6.

Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.

Hong K, Herrmann K, Dybala C, Halseth AE, Lam H, Foreyt JP.

Clin Obes. 2016 Oct;6(5):305-12. doi: 10.1111/cob.12157. Epub 2016 Aug 1.

7.

Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.

Mooney LJ, Hillhouse MP, Thomas C, Ang A, Sharma G, Terry G, Chang L, Walker R, Trivedi M, Croteau D, Sparenborg S, Ling W.

J Addict Med. 2016 Jul-Aug;10(4):236-43. doi: 10.1097/ADM.0000000000000218.

8.

Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial.

Mooney ME, Schmitz JM, Allen S, Grabowski J, Pentel P, Oliver A, Hatsukami DK.

Clin Pharmacol Ther. 2016 Oct;100(4):344-52. doi: 10.1002/cpt.402. Epub 2016 Jun 20.

9.

Company is blamed for early halt of trial into obesity treatment.

Wise J.

BMJ. 2016 Mar 8;352:i1363. doi: 10.1136/bmj.i1363. No abstract available.

PMID:
26962129
10.

Time-to-Event Analysis.

Tolles J, Lewis RJ.

JAMA. 2016 Mar 8;315(10):1046-7. doi: 10.1001/jama.2016.1825. No abstract available.

PMID:
26954413
11.

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.

Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR.

JAMA. 2016 Mar 8;315(10):990-1004. doi: 10.1001/jama.2016.1558.

PMID:
26954408
12.

Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted.

Sharfstein JM, Psaty BM.

JAMA. 2016 Mar 8;315(10):984-6. doi: 10.1001/jama.2016.1461. No abstract available.

PMID:
26954405
13.

What a waste!

[No authors listed]

Prescrire Int. 2015 Oct;24(164):232. No abstract available.

PMID:
26598763
14.

Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.

[No authors listed]

Prescrire Int. 2015 Oct;24(164):229-33.

PMID:
26594724
15.

Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.

Ali KF, Shukla AP, Aronne LJ.

Expert Rev Clin Pharmacol. 2016;9(1):27-34. doi: 10.1586/17512433.2016.1100072. Epub 2015 Oct 29. Review.

PMID:
26512740
16.

The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update.

Christou GA, Kiortsis DN.

Hormones (Athens). 2015 Jul-Sep;14(3):370-5. doi: 10.14310/horm.2002.1600. Review.

17.

Review of pharmacotherapy options for the management of obesity.

Bragg R, Crannage E.

J Am Assoc Nurse Pract. 2016 Feb;28(2):107-15. doi: 10.1002/2327-6924.12279. Epub 2015 Jun 25.

PMID:
26119641
18.

Naltrexone ER/Bupropion ER: A Review in Obesity Management.

Greig SL, Keating GM.

Drugs. 2015 Jul;75(11):1269-80. doi: 10.1007/s40265-015-0427-5. Review.

PMID:
26105116
19.

[Mysimba, an American appetite suppressant and the logic of the single European market].

Nau JY.

Rev Med Suisse. 2015 Apr 15;11(470):890-1. French. No abstract available.

PMID:
26050313
20.

Naltrexone extended-release plus bupropion extended-release for treatment of obesity.

Yanovski SZ, Yanovski JA.

JAMA. 2015 Mar 24-31;313(12):1213-4. doi: 10.1001/jama.2015.1617. No abstract available.

Supplemental Content

Loading ...
Support Center